An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction

Urologia Internationalis

Volumn 81, Issue 4, 2008, Pages 409-415

  Giammusso, Bruno ^a,i   Colpi, Giovanni M ^b   Cormio, Luigi ^c   Ludovico, Giuseppe ^d   Soli, Marcello ^e   Ponchietti, Roberto ^f   Montorsi, Francesco ^g   Panzironi, Claudio ^h   Guastella, Bruno ^h  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d Ospedale S Giacomo di Monopoli   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f UNIVERSITY HOSPITAL OF SIENA   (Italy)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^h PFIZER INC   (United States)

ⁱ NONE   (Italy)

Author keywords

Apomorphine; Erectile dysfunction; Sildenafil

Indexed keywords

APOMORPHINE; SILDENAFIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

ADULT; APOMORPHINE; CROSS-OVER STUDIES; DOPAMINE; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PURINES; QUESTIONNAIRES; RESEARCH DESIGN; SAFETY; SULFONES; TIME FACTORS; VASODILATOR AGENTS;

EID: 57649129152     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167838     Document Type: Article

References (9)

1. McKinlay JB: The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000;12:S6-S11.
2. Sildenafil Citrate (Viagra) US Package Insert. New York, Pfizer, 2002.
3. Altwein JE, Keuler FU: Oral treatment of erectile dysfunction with apomorphine SL. Urol Int 2001;67:257-263.
4. Dula E, Bukofzer S, Perdok R, George M: Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001;39:558-563.
5. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A: The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-830.
6. Althof SE, Corty EW, Levine SB, Levine F, Burnett AL, McVary K, Stecher V, Seftel AD: EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999;53:793-799.
7. Pavone C, Curto F, Anello G, Serretta V, Almasio PL, Pavone Macaluso M: Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J Urol 2004;172:2347-2349.
8. Eardley I, Wright P, MacDonagh R, Hole J, Edwards A: An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004;93:1271-1275.
9. Porst H, Behre HM, Jungwirth A, Burkart M: Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction: an open, randomized cross-over study with flexible dosing. Eur J Med Res 2007;12:61-67.